Drug Trial News

RSS

TAK-875 as effective as glimepiride in treating type 2 diabetes

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

27 Feb 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

New drug improves glycaemic control with minimum risk of hypoglycemia in type 2 diabetics

27 Feb 2012

FDA issues complete response letter for Watson's progesterone vaginal gel 8% NDA

Watson Pharmaceuticals, Inc. and Columbia Laboratories, Inc. today confirmed that, as expected, Watson has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.

27 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012

Researchers begin clinical trial of first visceral leishmaniasis vaccine

"Researchers say they've developed the first vaccine for visceral leishmaniasis (VL) -- a disease that affects 500,000 people each year and has been called the 'parasitic version of HIV,'" although the diseases are unrelated, U.S. News reports.

24 Feb 2012

Ipsen, Active Biotech report data from tasquinimod Phase II study on CRPC

Active Biotech's and Ipsen's castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.

24 Feb 2012

New CETP blockers continue to show promise as viable heart drugs

Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body.

23 Feb 2012

Varenicline improves walking ability in patients with SCA3

A nicotinic drug approved for smoking cessation significantly improved the walking ability of patients suffering from an inherited form of ataxia, reports a new clinical study led by University of South Florida researchers.

23 Feb 2012

Vemurafenib nearly doubles survival for patients with metastatic melanoma

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

23 Feb 2012

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid) and low dose dexamethasone in patients with relapsed multiple myeloma.

23 Feb 2012

IDRI launches LEISH-F3 + GLA-SE Phase 1 trial for kala-azar

The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place in Washington State, with a companion Phase 1 trial planned in India, an epicenter of the disease.

23 Feb 2012

Combination of gemcitabine and MRK003 kills pancreatic cancer cells

Cancer Research UK scientists have revealed how a combination of two very different drugs - currently being tested in clinical trials - amplifies the destruction of pancreatic cancer cells, according to research published in the Journal of Experimental Medicine, today.

22 Feb 2012

Immunization against flu during pregnancy can influence fetal growth

Vaccinating pregnant women against the influenza virus appears to have a significant positive effect on birth weight in babies, according to a study published in CMAJ.

22 Feb 2012

FDA to review rejected weight loss drug Qnexa

The weight loss pill Qnexa has been once rejected by the FDA over safety concerns. But this Wednesday it will get a second chance before an FDA advisory committee. Qnexa maker Vivus Inc. hopes something might come out of this second chance. The company will be submitting new safety data from patients who took Qnexa for a second year after completing a one-year clinical trial.

21 Feb 2012

GTx fourth quarter net loss increases to $10.7 million

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2011.

21 Feb 2012

S1 submits Lorexys IND application for HSDD and Female Sexual Dysfunction treatment

S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).

21 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012

Botox efficacy uncertain in treating migraine says NICE

Botox – used as an anti-wrinkle agent - is unlikely to be recommended for the treatment of chronic migraines on the NHS in England and Wales. According to the National Institute for Health and Clinical Excellence (NICE) draft guidelines there is insufficient evidence that it works.

18 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012